The London Pensions Fund Authority (LPFA) has appointed GlaxoSmithKline director of global pension investments Robert Vandersluis as a non-executive director to its board.
Figures from the LPFA's annual report 2013 showed the fund grew by £427m to £4.6bn between 2012 and 2013. Its valuation also revealed its funding level was around 95% (PP Online, 8 May). LPFA ch...
To continue reading this article...
Join Professional Pensions
Become a Professional Pensions Lite Member today
In just a few clicks you can start your free Professional Pensions Lite membership, providing you access to:
- Three complimentary articles per month covering the latest real-time news, analysis and opinion from the industry
- Receive important and breaking news stories via our two daily news alerts
- Hear from industry experts and other forward-thinking leaders
Are you a trustee, investment consultant or in-house pension and benefit scheme professional? You can apply for full complimentary access here
